scholarly journals Determination of ginsenoside-Rg1in human plasma and its application to pharmacokinetic studies following intravenous administration of ‘Shenmai’ injection

2009 ◽  
Vol 23 (1) ◽  
pp. 65-71 ◽  
Author(s):  
Liu Yang ◽  
Shun-jun Xu ◽  
Zhi-feng Wu ◽  
Yi-Ming Liu ◽  
Xing Zeng
Keyword(s):  
Human Plasma ◽  
Intravenous Administration ◽  
Pharmacokinetic Studies ◽  
Shenmai Injection

AN EFFICIENT HPLC-UV METHOD FOR THE QUANTITATIVE DETERMINATION OF CEFADROXIL IN HUMAN PLASMA AND ITS APPLICATION IN PHARMACOKINETIC STUDIES

2012 ◽  
Vol 35 (13) ◽  
pp. 1871-1881 ◽  
Author(s):  
Eunice Kazue Kano ◽  
Cristina Helena dos Reis Serra ◽  
Eunice Emiko Mori Koono ◽  
Kazuo Fukuda ◽  
Valentina Porta
Keyword(s):  
Quantitative Determination ◽  
Human Plasma ◽  
Pharmacokinetic Studies

Simultaneous determination of novel ketolide antibiotic nafithromycin and its major metabolite in human plasma using liquid chromatography tandem mass spectrometry

Bioanalysis ◽  
2019 ◽  
Vol 11 (19) ◽  
pp. 1767-1776
Author(s):  
Kiran R Patil ◽  
Ravindra D Yeole ◽  
Marcel de Zwart ◽  
Peter Pruim
Keyword(s):  
Phase I ◽  
Human Plasma ◽  
Internal Standard ◽  
Pharmacokinetic Studies ◽  
Simultaneous Quantification ◽  
Chromatography Tandem Mass Spectrometry ◽  
Liquid Chromatography Tandem Mass ◽  
Us Fda ◽  
Standard Protein

Aim: A sensitive method to quantify nafithromycin and its N-desmethyl metabolite in human plasma was necessary for Phase I pharmacokinetic studies. Methodology: A precise and accurate LC–MS/MS bioanalytical method has been developed and validated for the simultaneous quantification of nafithromycin (NFT, WCK 4873) and N-desmethyl metabolite (M1, WCK 4978) in human plasma. Clarithromycin was used as an internal standard. Protein precipitation technique was used as sample preparation approach. The calibration curve was linear (r ≥ 0.99) over the concentration range of 10–5000 ng/ml for NFT and M1. Method was validated as per US FDA guideline. Conclusion: The proposed method was successfully applied for determination of plasma levels of the NFT and M1 during Phase I clinical studies.

Determination of total or free cefazolin and metronidazole in human plasma or interstitial fluid by HPLC-UV for pharmacokinetic studies in man

2019 ◽  
Vol 1118-1119 ◽  
pp. 51-54 ◽  
Author(s):  
Christoph Dorn ◽  
Alexander Kratzer ◽  
Selina Schießer ◽  
Frieder Kees ◽  
Hermann Wrigge ◽  
...  
Keyword(s):  
Human Plasma ◽  
Interstitial Fluid ◽  
Pharmacokinetic Studies

scholarly journals Validated LC–MS/MS Assay for the Quantitative Determination of Fimasartan in Human Plasma: Application to Pharmacokinetic Studies

2015 ◽  
Vol 53 (8) ◽  
pp. 1250-1256 ◽  
Author(s):  
Seo Hyun Yoon ◽  
Seul Oh ◽  
Hwa Suk Kim ◽  
SoJeong Yi ◽  
Kyung-Sang Yu ◽  
...  
Keyword(s):  
Quantitative Determination ◽  
Human Plasma ◽  
Pharmacokinetic Studies

LC–MS–MS Quantitative Determination of Ursolic Acid in Human Plasma and Its Application to Pharmacokinetic Studies

2010 ◽  
Vol 72 (11-12) ◽  
pp. 1107-1113 ◽  
Author(s):  
Zhi-Rong Tan ◽  
Yao Chen ◽  
Gan Zhou ◽  
Shan Cao ◽  
Xiang-Dong Peng ◽  
...  
Keyword(s):  
Quantitative Determination ◽  
Human Plasma ◽  
Ursolic Acid ◽  
Pharmacokinetic Studies

Determination of Acotiamide in human plasma by LC-MS/MS and its application to a pharmacokinetic study

2020 ◽  
Vol 17 ◽  
Author(s):  
Qian Sun ◽  
Qiao-gen Zou ◽  
Yun-yan Xia ◽  
Cheng-qun Han
Keyword(s):  
Human Plasma ◽  
Pharmacokinetic Study ◽  
Ammonium Acetate ◽  
Internal Standard ◽  
Rat Plasma ◽  
Pharmacokinetic Studies ◽  
The Matrix ◽  
Liquid Chromatography Tandem Mass ◽  
Tandem Mass Spectrometric

Background: A liquid chromatography-tandem mass spectrometric (LC-MS/MS) method had been developed for the quantification of acotiamide in rat plasma and been applied to pharmacokinetic studies. However, there was no LC-MS/MS method been developed for the determination of acotiamide in human plasma and its pharmacokinetic study. Objective: A simple and fast LC-MS/MS method was established and validated for the quantification of acotiamide in human Received: plasma and was applied to a pharmacokinetic study. Methods: Sample preparation was accomplished Revised: Accepted: through protein precipitation, and chromatographic separation was achieved on a Welch, Ultimate XB-C18 column (2.1×50 mm, 3 μm) with a security guard cartridge C18 using a binary gradient with DOI: mobile phase A (Methanol) and B (the solution of 10 mM Ammonium acetate with 0.1% Formic acid) at a flow rate of 400 Results: The retention time of acotiamide and its internal standard, acotiamide-d6 was 1.78 min and 1.79 min, respectively. The total run time was 4.0 min. The method was developed and validated over the concentration range of 0.500-100 ng/mL for acotiamide, with correlation coefficient greater than 0.9987. The extraction recovery was more than 108.43% and the matrix effect was not significant. The inter- and intra-day precisions were below 5.80% and accuracies ranged from 92.7 to 103.0%. Acotiamide was demonstrated to be stable in human plasma under the tested conditions. Conclusion: The validated LC-MS/MS method was successfully applied to study the pharmacokinetic profiles of acotiamide in human plasma after oral administration and has achieved satisfactory results.

Sign in / Sign up

Export Citation Format

Share Document